Osimertinib

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Osimertinib (ncit:C116377)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (2) FDA (3) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib
EMA (2) FDA (3) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
EMA (1) FDA (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib
EMA (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib